Molecular Detection Inc. (MDI) is applying its proprietary technologies to develop and market Detect-Ready™ molecular diagnostic tests to increase the speed, accuracy, ease of use, and efficiency of infectious disease diagnosis.
DETECT-READY™ MRSA ASSAY:
MDI's first Detect-Ready™ assay is a ready-to-use, "sample-to-answer" rapid detection screening test for the growing problem of MRSA (methicillin-resistant S. aureus) infection, a costly and potentially deadly pathogen increasingly found in hospitals and other health facilities worldwide.
Molecular Detection Inc. (MDI) is developing and commercializing a portfolio of sample-to-answer Detect-Ready™ molecular diagnostic tests for the rapid detection of infectious diseases. The company is preparing to launch its first product, the Detect-Ready assay for the rapid diagnosis of MRSA.